Insights
Recon takes an analytical look behind select developments in healthcare
Keep up with Recon Strategy Insights
Get an email each time we publish a new article
Search
- By Jason Brauner, Phil Berk, and Lilian Zhang
Introduction
As we described in a prior whitepaper, explaining over- and under-performance of newly launched therapies relative to pre-launch expectations is a critical element to enabling robust prod…
- By Lilian Zhang, Jason Brauner, and Marc Herant
In our previous analyses (2023[1] and 2024[2]), we tracked two oncology development cohorts using a Kaplan–Meier framework to visualize how quickly programs reach a terminal outcome—either an FDA appr…
- By Chisom Chukwu
About the author: Chisom is currently a high school senior attending Boston Latin School. She spent the summer of 2025 with Recon Strategy as a paid intern assigned a project to research the effect of…
- By Marc Herant
Exercise with cancer: it’s about more than fitness
Retrospective observational studies very frequently highlight the correlation of various lifestyle characteristics with outcomes, but most of the tim…
- By Jacob Wiesenthal and Tory Wolff
A new AJMC study from consulting firm Recon Strategy is the first to show how advanced primary care techniques, previously proven in older Medicare populations, could also deliver substantial savings …
- By Jacob Wiesenthal and Tory Wolff
- By Martha Deja and Sarah Dolman
Download a PDF of this paper here. A comprehensive slide-deck (including a breakdown by therapeutic area) and a complete list of assets deals are also available; click [datapack] to access.
Ear…